A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs

Inclusion Criteria

• •Diagnosed to have psoriatic arthritis (PsA) of at least 3 months duration at screening.
• •Meets the Classification Criteria for Psoriatic Arthritis at Screening.
• •Active plaque psoriatic skin lesion(s) or documented medical history of plaque psoriasis (PsO) at screening.
• •Active arthritis as shown by ≥ 3 swollen joints and ≥ 3 tender joints at Screening and day 1.
• •Participant has high sensitivity C-reactive protein (hsCRP) ≥ 3 mg/L at Screening.
• •≥ 1 PsA-related hand and/or foot joint erosion on X-ray during Screening Period that is confirmed by central reading.
• •Must have completed the week 52 treatment for the optional open-label long-term extension period.